Equities research analysts expect that Aileron Therapeutics Inc (NASDAQ:ALRN) will report ($0.50) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Aileron Therapeutics’ earnings, with estimates ranging from ($0.62) to ($0.39). Aileron Therapeutics reported earnings per share of ($0.47) during the same quarter last year, which suggests a negative year over year growth rate of 6.4%. The firm is scheduled to issue its next quarterly earnings results on Monday, April 1st.
According to Zacks, analysts expect that Aileron Therapeutics will report full year earnings of ($2.27) per share for the current year, with EPS estimates ranging from ($2.37) to ($2.17). For the next year, analysts anticipate that the firm will report earnings of ($1.98) per share, with EPS estimates ranging from ($2.24) to ($1.63). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for Aileron Therapeutics.
Aileron Therapeutics (NASDAQ:ALRN) last issued its quarterly earnings results on Wednesday, November 7th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.08.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC bought a new position in Aileron Therapeutics in the first quarter worth about $151,000. Paloma Partners Management Co bought a new position in Aileron Therapeutics in the second quarter worth about $140,000. Renaissance Technologies LLC bought a new position in Aileron Therapeutics in the third quarter worth about $137,000. Bridgeway Capital Management Inc. lifted its holdings in Aileron Therapeutics by 78.6% in the third quarter. Bridgeway Capital Management Inc. now owns 113,600 shares of the company’s stock worth $312,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Parkwood LLC bought a new position in Aileron Therapeutics in the third quarter worth about $149,000. 12.72% of the stock is currently owned by hedge funds and other institutional investors.
Shares of ALRN stock traded down $0.01 during trading hours on Friday, hitting $2.05. 73,600 shares of the company were exchanged, compared to its average volume of 56,949. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.23 and a current ratio of 4.23. Aileron Therapeutics has a one year low of $1.75 and a one year high of $11.35. The stock has a market capitalization of $30.38 million, a price-to-earnings ratio of -1.16 and a beta of 0.04.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Read More: How to read a candlestick chart
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.